Business context and reporting period
BeiGene, Ltd. (the registrant named in the filing; the request metadata says “Beone Medicines”) filed this Form 10-K for the fiscal year ended December 31, 2020. The company is a commercial-stage biotechnology business focused on cancer medicines, with operations primarily in China and the United States. Q4 figures below are unaudited; the filing reports full-year results as its principal reporting period. Amounts are U.S. dollars.
Key financial metrics
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Product revenue, net | $308.9 million | $222.6 million |
| Collaboration revenue | — | $205.6 million |
| Total revenue | $308.9 million | $428.2 million |
| Cost of product sales | $70.7 million | $71.2 million |
| Research and development expense | $1,294.9 million | $927.3 million |
| Selling, general and administrative expense | $600.2 million | $388.2 million |
| Operating loss | $1,657.7 million | $959.9 million |
| Net loss attributable to BeiGene | $1,596.9 million | $948.6 million |
| Basic and diluted loss per share | $1.47 | $1.22 |
| Net cash used in operating activities | $1,283.5 million | $750.3 million |
Product revenue less product cost of sales implies a gross margin of approximately 77% in 2020, versus approximately 68% in 2019; the shift toward higher-margin internally developed products contributed to the improvement. Operating margin was approximately negative 537% in 2020, reflecting substantial development and commercialization spending.
At December 31, 2020, cash, cash equivalents and restricted cash totaled $1.390 billion and short-term investments were $3.269 billion, primarily U.S. Treasury securities. Total debt was $518.7 million, including $335.0 million short-term debt. Working capital was $3.885 billion; accumulated deficit was $3.553 billion. The company reported $1.821 billion in specified contractual obligations, including a remaining $1.019 billion Amgen co-development commitment.
Unaudited Q4 2020 revenue was $100.1 million and net loss was $472.6 million, compared with Q4 2019 revenue of $56.9 million and net loss of $387.9 million.
Material changes versus the prior comparable period
- Total revenue fell 27.9% year over year because 2019 included $205.6 million of collaboration revenue, including a $150 million payment associated with termination of the BMS tislelizumab collaboration. Product revenue grew 38.8%.
- Tislelizumab generated $163.4 million of 2020 sales after its China launch in March. BRUKINSA revenue increased to $41.7 million from $1.0 million, and XGEVA contributed $8.5 million after its 2020 launch. Declines in BMS-licensed products included ABRAXANE, down 84%, and REVLIMID, down 39%.
- R&D expense increased 39.6%, principally reflecting expanded development activity, $117.0 million of Amgen co-development expense, and higher upfront license payments. SG&A increased 54.6%, driven by hiring and commercial expansion.
- Net loss widened 68.3%. Operating cash use increased, while cash and investments rose substantially after $2.8 billion of proceeds related to Amgen and a $2.1 billion registered direct share offering. Debt also increased, partly to fund the purchase of the remaining minority interest in BeiGene Biologics and repay a shareholder loan.
Outlook, commentary, risks and unusual items
- Management expected 2021 product revenue to grow as internally developed and Amgen-licensed product launches matured. It also expected NRDL inclusion to expand access, while warning that negotiated lower prices would affect product revenue and margins. The filing provides no specific revenue or earnings guidance.
- Management said existing cash, cash equivalents and short-term investments were expected to fund operations and capital needs for at least 12 months after issuance of the financial statements, but might not fund all planned global development and launches.
- In January 2021, BeiGene signed a tislelizumab collaboration with Novartis for specified markets. The agreement provides for a $650 million upfront payment, up to $1.3 billion in regulatory milestones, $250 million in sales milestones, and tiered royalties. At filing, closing remained subject to regulatory waiting-period conditions; the upfront payment was not included in year-end liquidity.
- The NMPA suspended ABRAXANE importation, sales and use in China in March 2020 following inspection findings at a BMS contract manufacturing facility; BMS recalled existing stock. BeiGene reported no 2020 sales after the suspension and could not predict when supply and sales would resume.
- BeiGene initiated arbitration against BMS/Celgene over ABRAXANE supply obligations; the counterclaim sought approximately $17 million in recall costs. The company said it intended to defend the counterclaim and could not predict the outcome.
- Material risks include clinical-trial and regulatory uncertainty, competition and reimbursement/pricing pressure, reliance on contract manufacturers and distributors, rapid organizational growth, COVID-19 disruption, China-U.S. regulatory and geopolitical risks, currency controls, and the potential impact of restrictions on PCAOB inspection of the company’s auditor. The filing also states the auditor issued an unqualified opinion and management and auditor found internal control over financial reporting effective as of year-end.
Most important facts for investors to verify
- Whether product growth—especially tislelizumab and BRUKINSA—can offset lower prices after NRDL inclusion and declines in legacy licensed products.
- Timing and economic terms of ABRAXANE supply restoration, and the outcome and potential exposure in the related arbitration.
- Completion of the Novartis transaction and realization of its upfront payment, milestones and royalties.
- Cash burn, financing needs and debt maturities, alongside the remaining Amgen co-development commitment.
- Clinical and regulatory progress, including confirmatory studies for conditionally or accelerated-approved medicines and the safety profile of pipeline products.
- Developments in PCAOB audit access and related U.S. listing requirements, as well as any material changes in China regulatory, data-transfer or foreign-exchange rules.